In conjunction with a drug manufacturer’s plans to take Raptiva off the market, the Food and Drug Administration is recommending that psoriasis patients taking the medication consider alternatives.

After June 8, Raptiva will no longer be available due to its link to a neurological condition, progressive multifocal leukoencephalopathy, which can lead to "an irreversible decline in neurologic function and death," said the federal agency.

The drug, administered as a weekly injection to combat certain forms of plaque psoriasis, led to the deaths of three patients, and subsequent increases in warning labels by Genentech, its maker.

Alternative treatments often include tar-based topical solutions, and along with Ultraviolet B therapy, can reduce the incidence of psoriasis in up to 90 percent of psoriasis suffers, notes the National Psoriasis Foundation.

Another potential aid in combating psoriasis, which has been linked to immune system issues, may be fatty acids found in oily fishes. Recent research indicates that Omega-3s may benefit psoriasis sufferers because it improves immune system function.